Scarica l'app Stockscreener
4.01
2.69%
0.105
Dopo l'orario di chiusura:
4.01
Precedente Chiudi:
$3.905
Aprire:
$4
Volume 24 ore:
27,853
Relative Volume:
0.53
Capitalizzazione di mercato:
$21.59M
Reddito:
-
Utile/perdita netta:
$-2.17M
Rapporto P/E:
-0.2312
EPS:
-17.3434
Flusso di cassa netto:
$-4.82M
1 W Prestazione:
+9.56%
1M Prestazione:
+36.86%
6M Prestazione:
+73.59%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.81
$4.02
Intervallo di 1 settimana:
$3.40
$4.235
Portata 52W:
$1.8299
$6.48
Newcelx Ltd Stock (NCEL) Company Profile
Compare NCEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NCEL
Newcelx Ltd
|
4.01 | 21.02M | 0 | -2.17M | -4.82M | -17.34 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newcelx Ltd Borsa (NCEL) Ultime notizie
Enterprise value to revenue forward of NewcelX Ltd. – NASDAQ:NCEL - TradingView
NCELNewcelX Ltd Volatility & Greeks - Finviz
NewcelX Wins FDA Backing to Advance NCEL-101 Toward Type 1 Diabetes Trials - TipRanks
NewcelX receives FDA feedback on type 1 diabetes therapy plan - Investing.com
NewcelX Announces Successful FDA Pre-IND Meeting for NCEL-101 Type 1 Diabetes Program - Quiver Quantitative
NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes - marketscreener.com
NewcelX Shareholders Approve All Proposals at June 30 Annual Meeting - TipRanks
Number of shareholders of NewcelX Ltd. – NASDAQ:NCEL - TradingView
Number of shareholders of NewcelX Ltd. – BOATS:NCEL - TradingView
NewcelX Ltd. Actuals & Estimates (NASDAQ:NCEL) - TradingView
NewcelX Ord Shs (NCEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NCEL Should I Buy - Intellectia AI
NewcelX Ord Shs (NCEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewcelX Ord Shs (NCEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewcelX Ord Shs (NCEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
NewcelX Ord Shs (NCEL) Institutional Confidence - TradingKey
[EFFECT] NewcelX Ltd. SEC Filing - Stock Titan
NewcelX Ord Shs (NCEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewcelX Ord Shs (NCEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewcelX Ord Shs (NCEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NewcelX Ord Shs (NCEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exclusive: NewcelX eyes accelerated 2026 execution for diabetes drug - MSN
NewcelX Stem Cell Platform Strengthened by Peer-Reviewed AstroRx Study in Multiple Sclerosis - TipRanks
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform - The Manila Times
Peer-reviewed AstroRx data underscore NewcelX (NCEL) stem cell platform - Stock Titan
NewcelX Ltd. (NCEL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NewcelX Calls June 30, 2026 Shareholders’ Meeting as 2025 Losses Deepen - TipRanks
NewcelX Stock Moves Up Ahead of FDA Meeting on Diabetes Treatment - Bez Kabli
Exclusive: NewcelX advances diabetes therapy toward human trials with FDA pre-IND submission - MSN
NewcelX Ltd. (NCEL) Gains Ground: Testing Key Resistance LevelsStatistical Arbitrage - newsline.com
Newcelx submits pre-IND package for NCEL-101 to FDA - BioWorld News
NewcelX Files Pre-IND With FDA for NCEL-101 Type 1 Diabetes Cell Therapy - TipRanks
Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes - marketscreener.com
NewcelX (Nasdaq: NCEL) files FDA pre-IND for NCEL-101 diabetes cell therapy - Stock Titan
NewcelX Ltd. Schedules Pre-IND Meeting with FDA to Propel Type 1 Diabetes Treatment NCEL-101 into First-In-Human Trials - Quiver Quantitative
Stem cell therapy targeting a potential type 1 diabetes cure nears trials - Stock Titan
NCEL Stock Price, Quote & Chart | NEWCELX LTD (NASDAQ:NCEL) - ChartMill
TradingKey - TradingKey
NewcelX (NASDAQ: NCEL) registers 2.26M shares for resale by investors - Stock Titan
Why NewcelX (NCEL) is still under the radar (Risk Aversion) 2026-05-06Top Analyst Buy Signals - Newser
NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares - Quantisnow
NewcelX Ltd. (NCEL) updates resale prospectus for up to 500,000 shares - Stock Titan
How NewcelX (NCEL) differentiates itself from competitors (Investor Concern) 2026-05-05High Interest Stocks - newser.com
Julien Ruggieri Discloses Investment at NewcelX Ltd. with 25.3% Stake - TradingView
League Jinn holds 25.3% ownership stake in NewcelX (NCEL) - Stock Titan
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug - Yahoo Finance
NLSPW SEC FilingsNEWCELX LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Olivier Samuel Buys Handful Of Shares In NewcelX - 富途牛牛
Despite NewcelX's Pullback, Insiders Still Gained ₪136k - Yahoo Finance
NewcelX Loses US$2.3m Market Value But Insiders See Windfall Of ₪136k - simplywall.st
Newcelx Ltd Azioni (NCEL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Newcelx Ltd Azioni (NCEL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Revel Michel | CSO and Director |
Apr 27 '26 |
Buy |
2.75 |
54,545 |
149,999 |
957,530 |
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):